NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit-sub ...

Core Viewpoint - The Schall Law Firm is investigating Centene Corporation for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Centene issued false or misleading statements and failed to disclose critical information to investors [2]. - A Seeking Alpha report indicated that Centene's shares declined after the company withdrew its 2025 earnings guidance, citing higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - Following the announcement, Centene's shares fell by more than 39.5% during intraday trading on the same day [2]. Group 2: Company Background - Centene Corporation is involved in providing healthcare services, particularly through Medicaid and Affordable Care Act plans [2]. - The company reported a significant increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2].

Core Insights - Elevance Health (NYSE: ELV) is scheduled to report earnings on July 17, 2025, with analysts projecting earnings of $9.19 per share on revenue of $48.26 billion, compared to $10.12 per share and $43.22 billion in the same quarter last year [3][4] Group 1: Stock Performance and Historical Data - Over the last five years, Elevance Health has experienced positive one-day stock returns in 55% of cases following earnings announcements, with a median positive return of 2.7% and a maximum return of 7.7% [3][7] - In the past five years, there have been 18 earnings data points, resulting in 11 positive and 7 negative one-day returns, leading to a positive return rate of approximately 61%, which increases to 73% when considering the last three years [7] Group 2: Financial Metrics - Elevance Health currently has a market capitalization of $77 billion and has generated $183 billion in revenue over the past twelve months, with a net income of $5.9 billion [4] Group 3: Trading Strategies - Traders can adopt two primary strategies around earnings announcements: pre-earnings positioning and post-earnings positioning, evaluating immediate and medium-term returns to inform trading actions [6] - A lower-risk strategy involves understanding the correlation between short-term and medium-term returns following earnings, allowing traders to take positions based on the strongest correlations observed [8][9]

Core Viewpoint - CVS Health Corporation is gaining investor attention as its stock trends higher ahead of its second-quarter earnings release, driven by the removal of proposed Medicare Pharmacy Benefit Manager limits from the Senate's tax bill, alleviating regulatory pressure on the company [1][11]. Group 1: Financial Performance - CVS Health reported a strong first-quarter 2025 performance with a 7% year-over-year revenue increase and adjusted EPS rising to $2.25 from $1.31 a year earlier [7][8]. - The company raised its full-year adjusted EPS guidance to a range of $6.00–$6.20, up from $5.75–$6.00, and expects around $7 billion in cash flow [7][8]. - The Zacks Consensus Estimate for CVS's 2025 earnings per share suggests a 12.9% improvement from 2024 [9]. Group 2: Market Position and Competitive Landscape - CVS Health has staged a notable turnaround in 2025, recovering nearly 50% year-to-date after facing challenges such as the closure of approximately 900 stores between 2022 and 2024 [3][8]. - In comparison, archrivals like Cigna grew 10.9% while UnitedHealth shares dipped 39.2% during the same period [4]. Group 3: Business Segments and Growth Drivers - Growth was broad-based across CVS's three business segments: Health Care Benefits (8% growth), Health Services (7.9% growth), and Pharmacy & Consumer Wellness (11.1% growth) in the first quarter [9]. - Aetna, CVS's insurance unit, benefited from higher Medicare Advantage star ratings and favorable prior-year cost adjustments, reinforcing earnings momentum [9]. Group 4: Regulatory Environment and Strategic Initiatives - The Senate's decision to drop proposed limits on PBMs and cuts to Medicare Advantage removes a key regulatory risk for CVS's Caremark unit and supports stable revenues for Aetna [11]. - CVS is enhancing care delivery by processing 95% of prior authorizations within 24 hours and expanding value-based care into oncology and cardiology [12]. Group 5: Valuation and Investment Outlook - CVS Health's forward 12-month price-to-earnings (P/E) ratio is 9.83X, which is a discount to the S&P 500's 22.63X and slightly above Cigna's P/E of 9.63X [15][16]. - The stock's premium over Cigna may be justified by its scale, efficiency, and strategic focus on digital health, AI, and value-based care, presenting an attractive entry point for long-term investors [17]. - With strong operational momentum and easing regulatory headwinds, CVS Health is positioned as a solid buy ahead of its second-quarter earnings [18].

Health insurer Elevance Health Inc. ELV is scheduled to release its second quarter 2025 financial results on July 17.Analysts estimate adjusted earnings of $9.197 per share on sales of $48.24 billion, as per data from Benzinga Pro.UnitedHealth Group Inc. UNH has been the first major health insurer to report quarterly earnings for several quarters. However, this quarter, the insurance giant will release its second quarter 2025 financial results on July 29.As it’s the biggest player in the industry, Forbes wr ...

Core Viewpoint - Ferguson Wellman Capital Management sold a significant portion of its shares in UnitedHealth Group, indicating potential concerns about the company's performance and outlook [1][2]. Company Overview - UnitedHealth Group is one of the largest healthcare companies in the U.S., operating across insurance, care delivery, and pharmacy benefit management, which supports a broad customer base and recurring revenue streams [4]. - The company reported a trailing twelve months (TTM) revenue of $410.06 billion and a net income of $22.11 billion, with a dividend yield of 2.95% [2][6]. Recent Performance - UnitedHealth's stock has underperformed significantly, with a one-year price change of -41.5%, and it is trading 52.5% below its 52-week high as of July 9, 2025 [5][10]. - The stock closed at $304.10 on July 11, 2025, and has underperformed the S&P 500 by 52.8 percentage points over the past year [5]. Challenges Faced - The company has faced multiple challenges, including a significant rise in medical costs, leading to a withdrawal of its earnings guidance [5][10]. - Allegations of Medicare billing fraud and secret bonuses to nursing homes have surfaced, contributing to a turbulent year for the company [8][9]. - The abrupt resignation of CEO Andrew Witty in mid-May has added to the company's instability [8]. Future Outlook - Despite current challenges, UnitedHealth has appointed former CEO Stephen J. Hemsley back to the role and expects to return to growth in 2026, with long-term earnings per share growth projected at 13% to 16% [10].

Core Viewpoint - Analysts forecast that Elevance Health (ELV) will report quarterly earnings of $9.20 per share, indicating a year-over-year decline of 9.1%, while revenues are expected to reach $48.13 billion, reflecting an increase of 11.4% compared to the previous year [1] Revenue Estimates - The consensus estimate for 'Revenues- Premiums' is $39.62 billion, suggesting a year-over-year increase of 11.9% [5] - 'Revenues- Service fees' are expected to be $2.24 billion, indicating a decline of 1.8% year over year [5] - 'Revenues- Net investment income' is projected at $464.67 million, reflecting a decrease of 8.5% from the year-ago quarter [5] - 'Revenues- Product revenue' is forecasted to reach $6.14 billion, showing an increase of 11.1% from the previous year [6] Membership Estimates - 'Medical Membership - Medicare - Medicare Supplement' is expected to be 868.88 thousand, down from 894.00 thousand year over year [6] - 'Medical Membership - Commercial Risk-Based - Employer Group Risk-Based' is projected at 3.64 million, slightly down from 3.65 million in the same quarter last year [7] - 'Medical Membership - Commercial Risk-Based' is estimated at 5.00 million, up from 4.93 million year over year [7] - Total Medical Membership is expected to be 45.83 million, a slight increase from 45.78 million year over year [8] - 'Medical Membership - Medicare - Medicare Advantage' is projected to reach 2.24 million, up from 2.03 million year over year [8] - 'Medical Membership - Medicaid' is expected to be 8.86 million, down from 9.03 million year over year [9] - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.65 million, slightly down from 1.66 million year over year [9] Stock Performance - Over the past month, shares of Elevance Health have returned -11.4%, contrasting with the Zacks S&P 500 composite's +4% change [9]

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). Shareholders who purchased shares of CNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investor ...

Core Insights - UnitedHealth Group Inc. (UNH) experienced a significant Power Inflow, indicating potential upward movement in its stock price [3][4] - The Power Inflow occurred at a price of $299.78, suggesting a bullish signal for traders [4][8] - Following the Power Inflow, UNH's stock reached a high price of $304.10, reflecting a return of 1.4% [8] Trading Signals - The Power Inflow is a crucial trading signal that helps gauge the stock's overall direction based on institutional activity [6] - Order flow analytics, which analyze the flow of buy and sell orders, are utilized to make informed trading decisions [5][7] - Active traders interpret the Power Inflow as a bullish signal, indicating a potential entry point for capitalizing on upward trends [5][6] Market Context - The Power Inflow typically occurs within the first two hours of market open, influencing the stock's trend for the remainder of the day [6] - Incorporating order flow analytics can enhance trading performance by identifying opportunities and interpreting market conditions [7] - The importance of a trading plan that includes profit targets and stop losses is emphasized, reflecting the need for effective risk management [8]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 2: Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 3: Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price plummeted by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].